Table 1.

Summary of results for liver-directed therapy of neuroendocrine tumour liver metastases.

Modality author [Ref]	Intervention	Number of patients	Overall survival (5  years)	Median survivals (months)	Progression/disease-free survival	Clinical response	Biochemical response	Radiological response
Liver surgery
Sarmiento et al. [3]	Resection	170	61%
Touzios et al. [4]	Resection ± ablation	18	72%	>96
Grazi et al. [5]	Resection	19	92% (4 yrs)
Kianmanesh et al. [6]	Resection	23	94%		50% (5 yrs)
Gomez et al. [7]	Resection	18	86%		66% (5 yrs)
Scigliano et al. [8]	Resection	41	79%		3% (5 yrs)
Osborne et al. [9]	Cytoreduction	61		Curative-50 (mean)
				Palliative-32 (mean)
Musunuru et al. [10]	Resection ± ablation	13	83% (3 yrs)
Mayo et al. [11]	Resection ± ablation	339	74%	125
Liver transplantation
Lehnert [12]		103	47%
Olausson et al. [13]		15	90%		20% (5 years)
Le Treut et al. [14]		85	47%
Embolisation
Ho et al. [15]	TAE or TACE	46		42	18 months
Ruutiainen et al. [16]	TACE	57	50%		35% (3 yrs)
Strosberg et al. [17]	TAE	84		36
Dong and Carr [18]	TACE	123	36%	39 (mean)
Ruszniewski et al. [19]	TACE	24				73%	57%	33%
Gupta et al. [20]	TAE or TACE	69 (Carcinoid)			22 months			67%
		54 (Pancreatic)			16 months			35%
RFA
Mazzaglia et al. [21]		63		46 (after  RFA)		70%
SIRT
King et al. [22]		37		29 (mean)		55%	43%	50%
Kennedy et al. [23]		148		70				63%
Cao et al. [24]		58	47% (3 yrs)	36				34%
Saxena et al. [25]		48		35				55%